ACROBiosystems社 DLL3: an emerging target in small cell lung cancer
|
|
|||||||||||||
|
|||||||||||||
|
DLL3: an emerging target in small cell lung cancer
|
|||||||||||||
|
Small cell lung cancer (SCLC) is a subtype of lung cancer, which accounts for about 15% of all lung cancer cases. Delta-like 3 (DLL3) is an attractive target for SCLC immunotherapy since its expression is highly restricted to SCLC with a neglectable appearance on normal adult tissues.
|
|||||||||||||
|
|
ACROBiosystems has developed an exclusive collection of DLL3 proteins to support the development of DLL3-targeted therapy.
・FITC\Biotin labeled DLL3 proteins.
・Ideal for anti- DLL3 CAR expression and antibody screening.
・More species and tags to choose from. |
||||||||||||
Hot Product List
More DLL3 related products
> Learn more about targets of CAR-T cell therapy.
> Learn more about anti-FMC63 scFv antibody. > Learn more about CD19 proteins. |
|||||||||||||
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。
